Advertisement
100% x 90

HAS-BLED Calculator

Assess bleeding risk in atrial fibrillation patients on anticoagulation

HAS-BLED Risk Factors Assessment

Select "Yes" for any bleeding risk factors present in your patient. Each factor adds 1 point to the HAS-BLED score.

H - Hypertension

Systolic blood pressure > 160 mmHg (uncontrolled hypertension)

A - Abnormal Renal Function

Dialysis, transplant, or creatinine > 200 µmol/L (2.26 mg/dL)

S - Abnormal Liver Function

Cirrhosis or bilirubin > 2x ULN or AST/ALT/AP > 3x ULN

B - Bleeding History

Previous major bleeding or predisposition to bleeding

L - Labile INR

Time in therapeutic range < 60% (unstable/high INRs)

E - Elderly

Age ≥ 65 years

D - Drugs

Antiplatelet agents, NSAIDs, or other bleeding-predisposing drugs

S - Stroke History

Previous stroke or TIA

A - Alcohol Use

≥ 8 standard drinks per week

HAS-BLED Score Results

0
HAS-BLED Score
Low Risk

Annual Bleeding Risk

0.9%
1.1 events per 100 patient-years

Clinical Recommendation

Consider anticoagulation therapy. Low bleeding risk.

Example Patient Case

Patient: 72-year-old with Atrial Fibrillation

Medical History: Hypertension (well-controlled), previous stroke

Current Medications: Taking aspirin daily

Age: 72 years (≥65)

Laboratory: Normal renal and liver function

Anticoagulation: Good INR control

HAS-BLED Score Calculation

H - Hypertension: No (well-controlled, SBP < 160)

A - Abnormal renal: No

S - Abnormal liver: No

B - Bleeding history: No

L - Labile INR: No

E - Elderly: Yes (+1 point)

D - Drugs: Yes (+1 point, aspirin)

S - Stroke: Yes (+1 point)

A - Alcohol: No

Total HAS-BLED Score: 3 (High Risk, 3.7% annual bleeding risk)

Advertisement
100% x 250

Risk Interpretation

Low Risk (0-1)

0.9-1.3% annual risk

Consider anticoagulation

Moderate Risk (2)

2.2% annual risk

Can consider with caution

High Risk (≥3)

3.7-8.7% annual risk

Consider alternatives

HAS-BLED Mnemonic

HHypertension
AAbnormal renal/liver
SStroke history
BBleeding
LLabile INR
EElderly (≥65)
DDrugs/alcohol

Major Bleeding Definition

Fatal bleeding

Clinically overt bleeding

Hb drop ≥20 g/L

≥2 units transfusion

Critical anatomic site

Understanding the HAS-BLED Score

Purpose and Application

The HAS-BLED score is a validated clinical tool designed to assess the 1-year major bleeding risk in patients with atrial fibrillation who are being considered for or are already on anticoagulation therapy.

Clinical Validation

Developed by Pisters et al. (2010), this score has been extensively validated and is recommended by international guidelines for bleeding risk assessment in AF patients.

Key Principles

Important Considerations:

  • • Not meant to exclude patients from anticoagulation
  • • Helps identify high-risk patients for closer monitoring
  • • Focus on modifiable risk factors
  • • Balance bleeding vs. stroke risk

Important: High bleeding risk should prompt consideration of reversible factors and enhanced monitoring, not automatic exclusion from anticoagulation.

Clinical Decision Making

Low Risk (0-1)

Proceed with anticoagulation as clinically indicated. Monitor according to standard protocols.

Moderate Risk (2)

Consider anticoagulation with enhanced monitoring. Address modifiable risk factors.

High Risk (≥3)

Carefully weigh risks vs benefits. Consider alternatives. Frequent monitoring and risk factor modification essential.

Risk Factor Modification Strategies

Modifiable Factors

  • • Optimize BP control (target < 140/90)
  • Bleeding predisposition: Treat anemia, peptic ulcers
  • Labile INR: Improve anticoagulation management
  • Alcohol: Reduce or eliminate alcohol consumption
  • Drugs: Review and discontinue unnecessary bleeding-risk medications

Non-modifiable Factors

  • Age: Enhanced monitoring in elderly patients
  • Stroke history: Consider in risk-benefit analysis
  • Renal dysfunction: Dose adjustment may be needed
  • Liver disease: May affect anticoagulant metabolism

Important Medical Disclaimer

This HAS-BLED calculator is designed for educational purposes and clinical reference only. It should never replace comprehensive clinical assessment or professional medical judgment regarding anticoagulation therapy.

Healthcare professionals should:

  • Use HAS-BLED as part of comprehensive atrial fibrillation management
  • Balance bleeding risk with stroke risk (CHA2DS2-VASc score)
  • Consider individual patient factors beyond the calculated score
  • Follow current AF guidelines (ESC, AHA/ACC/HRS)
  • Address modifiable bleeding risk factors when possible
  • Never use high bleeding risk alone to exclude anticoagulation

This tool is based on the original HAS-BLED validation studies and should be used in conjunction with current evidence-based guidelines for atrial fibrillation management and anticoagulation therapy.

Advertisement
100% x 250